The DAP-CORONA RCT is a phase III randomized, triple-blind, placebo-controlled multicentre study on the efficacy and safety of Dapsone in adult patients who have been presenting with symptoms, have been diagnosed with COVID-19 infection and are at high risk of developing complications and requiring hospitalization. Approximately 3 000 individuals who meet the eligibility criteria of this trial will be selected to receive either Dapsone, a generic drug, or placebo tablets for 21 days on a random basis.
Eligible participants will receive the trial medication delivered straight to their doorsteps. During the trial, they will be directly but remotely monitored and supported through the DAP-CORONA VirtualCare platform.
ELIGIBILITY
If you answer YES to all of the points below, you are invited to contact the DAP-CORONA trial team to find out if you are eligible.
Please call study toll free line: 1-866-DAPC-RCT (1-866-327-2728)
or
Text ‘DAPC‘ to 1-833-4-SMS-DAP (1-833-476-7327)
You are 40 years of age or over.
You are presenting symptoms of COVID-19 in the last four days.
You have tested positive for COVID-19 or have submitted a test sample and waiting for the result or considering taking the COVID-19 test
Our study sites are located in:
CANADA
Montreal, Quebec
Toronto, Ontario
USA
High Point, North Carolina
Philadelphia, Pennsylvania
Spokane, Washington State
